Video

Dr. Johnson on the Clinical Potential of AMG 757 in SCLC

Melissa L. Johnson, MD, discusses the clinical potential of AMG 757 in patients with small cell lung cancer.

Melissa L. Johnson, MD, director of Lung Cancer Research at Sarah Cannon Research Institute, Tennessee Oncology, discusses the clinical potential of AMG 757 in patients with small cell lung cancer (SCLC).

AMG 757 is just one example of a novel immune mechanism that is currently being explored in SCLC, according to Johnson. Bispecifics present a promising opportunity to advance immuno-oncology in SCLC, similar to what has been done in non–small cell lung cancer with the advent of immune checkpoint inhibitors, Johnson continues. There are opportunities beyond adding an immune checkpoint inhibitor to chemotherapy in this patient population, with several innovative strategies coming down the pipeline, Johnson concludes.

Related Videos
Steven H. Lin, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.